Polycythemia vera

Polycythemia vera (PI) is a hematological disorder characterized by increased production of red blood cells (erythrocytes), and often an increase in the number of white blood cells and platelets. This disease belongs to the group of myeloproliferative neoplasms and is associated with a mutation in the JAK2 gene. PI leads to an increase in blood viscosity, which can cause clinical manifestations including headache, visual disturbances, and an increased risk of venous and arterial thrombosis. An important aspect is that polycythemia vera can be asymptomatic for a long time, and its late diagnosis often leads to complications and disease progression.

History of the disease and interesting historical facts

Polycythemia vera was first described in 1892 by Viennese physician Carl Jakob, who referred to it as “policemia.” Since then, the disease has undergone significant changes in understanding, particularly with the discovery of its molecular mechanisms. In 2005, the discovery of the JAK2 V617F mutation, which is key to the pathogenesis of PI, was a significant step forward in the diagnosis and treatment of this condition. Interestingly, polycythemia vera was previously considered a relatively rare disease; modern epidemiology shows that it has become more common due to improved diagnostic methods and increased physician awareness. In 2016, the World Health Organization (WHO) officially included PI in the classification of myeloproliferative neoplasias, facilitating knowledge aggregation and access to targeted therapeutic approaches.

Epidemiology

According to statistics, polycythemia vera occurs in approximately 2-3 cases per 100,000 people per year. The prevalence of this disease may vary depending on the geographic region. For example, data show that in Northern Europe, the incidence rate can reach 10 cases per 100,000 people, while in some other regions of the world, the rates are around 1 case per 100,000 people. The age peak of the disease is observed on average in people over 60 years old, but cases of the disease in younger patients are becoming more frequent. The ratio of men to women is approximately 2:1, which indicates some predisposition to this condition in men.

Genetic predisposition to this disease

Polycythemia vera is directly associated with a mutation in the JAK2 gene, which is found in more than 90% patients with this diagnosis. The JAK2 V617F mutation leads to constitutive activation of the signal transduction pathway, which causes uncontrolled proliferation of blood and its elements. In addition to JAK2, mutations in the MPL and CALR genes have been described in some cases, which can also contribute to the development of myeloproliferative diseases. Studies show that the presence of these mutations may have prognostic value and clients with certain genetic markers may require more aggressive treatment and monitoring.

Risk factors for the development of this disease

Risk factors for polycythemia vera can be divided into several categories:

• Age: The vast majority of cases occur in people over 60 years of age.
• Male gender: Men are affected more often than women, which may be due to hormonal or genetic factors.
• Smoking: Smoking is associated with increased levels of erythropoietin and may accelerate the progression of the disease.
• Living at high altitude: Long periods of exposure to low oxygen levels can result in a compensatory increase in red blood cells.
• Immediate medical history: A family history of polycythemia or other myeloproliferative disorders may indicate a familial predisposition.

Diagnosis of this disease

Diagnosis of polycythemia vera begins with a clinical assessment and anamnesis. The main symptoms that may alert doctors include:

• Headaches
• Visual impairment
• Itching, especially after a hot bath
• Enlarged spleen
• Thrombus formation

Laboratory tests include a complete blood count, which shows elevated hemoglobin and hematocrit levels and may also reveal elevated white blood cell and platelet counts. Radiologic tests may include ultrasound to evaluate the size of the spleen and liver. Imaging tests, such as bone marrow biopsy, help confirm the presence of JAK2 mutations and also reveal morphologic changes in the cells. The differential diagnosis includes conditions such as secondary erythrocytosis, Eikendahl syndrome, and other myeloproliferative disorders.

Treatment

Treatment for polycythemia vera is aimed at reducing red blood cell levels and preventing blood clots. Common approaches include:

• Phlebotomy: Regular removal of blood to reduce the hematocrit to normal levels.
• Pharmacological treatment: Low-dose aspirin to reduce blood viscosity and prevent thrombus formation; hydroxyurea to reduce cell production.
• Surgical treatment: In rare cases, splenectomy may be required in patients with severe hypersplenism.
• Other methods: Interferon-alpha and other targeted drugs such as ruzerem are used to moderate symptoms and control the disease.

List of medications used to treat this disease

Treatment options for polycythemia vera may include:

• Hydroxyurea
• Aspirin
• Interferon alpha
• Ruzerem
• Folic acid

Disease monitoring

Monitoring the condition of patients with polycythemia vera includes regular controlled steps such as:

• Frequent monitoring of hemoglobin and hematocrit levels
• Evaluation for the presence of thrombus formation
• Monitoring possible side effects from prescribed treatment

The prognosis of the disease varies depending on timely diagnosis and treatment. In most patients, with adequate therapy, it is possible to achieve normal hemoglobin levels and reduce the risk of thrombosis. However, without treatment, complications such as thrombosis, bleeding, and transformation into aggressive forms of myeloproliferative diseases may develop.

Age-related features of the disease

Polycythemia vera may present differently in different age groups. Elderly patients are more likely to develop thrombosis and complications, while younger patients may initially be asymptomatic but are more likely to progress to more serious forms. In children, polycythemia vera is much less common; however, when it does occur, it may be due to a hereditary predisposition and requires special attention in treatment approaches.

Questions and Answers

• What is polycythemia vera?
  Polycythemia vera is a myeloproliferative disorder characterized by increased production of red blood cells, leading to increased blood viscosity and an increased risk of blood clots.
• How is polycythemia vera diagnosed?
  Diagnosis includes clinical examination, blood tests for hemoglobin and hematocrit levels, tests for mutations in the JAK2 genes and morphological changes in bone marrow cells.
• What is the treatment for polycythemia vera?
  Treatment includes phlebotomy, drug therapy (hydroxyurea, aspirin), and in some cases surgery to reduce blood cell production.
• What are the risk factors associated with the disease?
  Major risk factors include older age, smoking, male gender, and a family history of myeloproliferative disorders.
• What is the prognosis for patients with polycythemia vera?
  The prognosis is good with timely diagnosis and adequate treatment, but serious complications are possible if the disease remains uncontrolled.